First Trust Advisors LP Has $35.71 Million Stock Position in Elanco Animal Health Incorporated $ELAN

First Trust Advisors LP boosted its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 37.0% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,500,822 shares of the company’s stock after purchasing an additional 675,497 shares during the period. First Trust Advisors LP owned 0.50% of Elanco Animal Health worth $35,712,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently made changes to their positions in ELAN. First Horizon Advisors Inc. raised its stake in shares of Elanco Animal Health by 184.3% during the 2nd quarter. First Horizon Advisors Inc. now owns 3,724 shares of the company’s stock worth $53,000 after purchasing an additional 2,414 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its position in Elanco Animal Health by 261.6% during the second quarter. Caitong International Asset Management Co. Ltd now owns 4,039 shares of the company’s stock worth $58,000 after acquiring an additional 2,922 shares in the last quarter. Covestor Ltd lifted its stake in Elanco Animal Health by 510.9% in the first quarter. Covestor Ltd now owns 7,087 shares of the company’s stock valued at $74,000 after acquiring an additional 5,927 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Elanco Animal Health by 26.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 6,379 shares of the company’s stock valued at $91,000 after acquiring an additional 1,332 shares during the period. Finally, Parallel Advisors LLC increased its stake in shares of Elanco Animal Health by 66.6% during the 2nd quarter. Parallel Advisors LLC now owns 6,432 shares of the company’s stock worth $92,000 after purchasing an additional 2,572 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Trading Down 5.7%

ELAN stock opened at $20.45 on Wednesday. Elanco Animal Health Incorporated has a 52 week low of $8.02 and a 52 week high of $23.70. The company has a market capitalization of $10.16 billion, a PE ratio of 340.96, a price-to-earnings-growth ratio of 2.94 and a beta of 1.86. The company’s 50-day simple moving average is $21.69 and its 200 day simple moving average is $17.93. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.23 and a current ratio of 2.40.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $0.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.06. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The firm had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.09 billion. During the same quarter in the previous year, the firm posted $0.13 EPS. The business’s revenue for the quarter was up 10.4% compared to the same quarter last year. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. As a group, sell-side analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on ELAN shares. Argus upgraded shares of Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 target price for the company in a research note on Wednesday, November 19th. JPMorgan Chase & Co. raised Elanco Animal Health from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $18.00 to $24.00 in a research report on Tuesday, October 7th. Stifel Nicolaus boosted their target price on Elanco Animal Health from $18.00 to $23.00 and gave the stock a “buy” rating in a report on Wednesday, September 24th. Barclays started coverage on Elanco Animal Health in a research note on Tuesday. They issued an “overweight” rating and a $30.00 price target on the stock. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Elanco Animal Health in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $22.78.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.